– USA, CA – ExThera Medical Corporation, a privately-held medical technology company focused on the therapeutic reduction of drug-resistant pathogens and sepsis mediators in whole blood, today announced the appointment of Dr. Michael Porter, Ph.D. to its board of directors.
“Dr. Porter’s global expertise in the strategic development of commercial organizations, his work on transformation of healthcare, and his relationships with numerous health systems and delivery organizations, will provide a new and welcomed perspective to ExThera as we expand the markets for our novel blood filter,” said Board Chairman, Bob Ward. “Michael will provide world class guidance as a strategic advisor to the Company. We are excited to welcome him to the Board as we begin a period of significant growth.”
ExThera’s Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100) has a CE Mark in Europe for the treatment of a wide range of bloodstream infections. In the USA Seraph 100 has Emergency Use Authorization from FDA, where it is being used successfully in the treatment of COVID-19 patients, many of whom are critically ill.
About Professor Michael Porter
Professor Porter, the Bishop William Lawrence University Professor at Harvard Business School, is recognized as a leading authority on competitive strategy, the competitiveness and economic development of nations and regions, and the application of competition and strategy principles to address social problems such as health care, the environment, and creating economic opportunity by increasing corporate social impact. Harvard University and Harvard Business School jointly created the Institute for Strategy and Competitiveness dedicated to furthering Professor Porter’s research.
In addition, he has founded several non-profit organizations including the Initiative for a Competitive Inner City (ICIC), focused on revitalizing distressed economic urban communities, and the International Consortium for Health Outcome Measurements (ICHOM), the leader in developing patient-centered health outcomes by a medical condition, today encompassing 33 conditions affecting a substantial part of the disease burden.
Professor Porter holds a Bachelor’s degree in aerospace engineering from Princeton University where he was elected to Phi Beta Kappa, a Master’s degree in Business Administration with high distinction from Harvard Business School where he was a George F. Baker Scholar, and a Ph.D. in Business Economics from Harvard University.
He has also been awarded numerous honorary doctorates from universities around the world. He is a member of the Princeton University Board of Trustees and the author of 20 books and over 150 articles. Professor Porter also co-chairs the editorial board for the New England Journal of Medicine Catalyst, a leading journal for new approaches to health care delivery.
Professor Porter said: “I am truly excited about ExThera Medical’s business potential, and I am honored to be affiliated with this life-saving company at a time when medical innovation is more important than ever. ExThera Medical is a leading innovator in health technology and treating some of the most challenging and life-threatening medical conditions of our time.”
About ExThera Medical
Based in Martinez, California, near San Francisco, and in Vaals, The Netherlands, ExThera Medical Corporation is a privately held medical device company developing innovative blood filters capable of removing a broad range of harmful substances from the blood. The company develops therapeutic products to treat patients in the hospital or clinic, during epidemics, or on the battlefield. Led by an accomplished management team with decades-long experience in the development and manufacture of blood-contacting implants, devices, and enabling biomaterials technology, the company has strong patent protection and a growing body of data from independent laboratory studies, from its participation in DARPA’s Dialysis-Like Therapeutics program, and from successful clinical use in the EU.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.